Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist

WEST BEND, Wis., April 30 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink sheets: MNCN), a manufacturer and distributor of products for animal health, announced today the appointment of Dr. Peter C. Nash, Ph.D. as Chief Scientific Officer.

In his new role, Dr. Nash will be responsible for spearheading Mach One's development activities in innovative antibody technologies for use in the dairy, beef, poultry, and swine markets.

Dr. Nash is a microbiologist with over 30 years of experience in 13 areas of medicine, from parasitology to immunology to virology. He has been a professor at the Indiana School of Medicine, University of Minnesota and Minnesota State University, Mankato. Throughout the past 25 years he was involved in a variety of roles researching and developing rapid human diagnostics to agriculture -- researching Campylobacter, Pasteurella and E. coli 0157:H7. Dr. Nash developed quick swab tests to detect Listeria in feedlots and E. coli in processing plants. Dr. Nash also developed tests for strep, whooping cough, salmonella, toxins and other diagnostics. During the first Gulf War, he worked on anthrax tests until government funding dissipated. Along with two others, Dr. Nash spun off Camas Inc. From the University Technical Center in Minneapolis, they expanded their work and under the direction of Dr. Nash, Camas did work for the U.S. Department of Defense, the U.S. Marine Corps, and the U.S.D.A. After nearly three decades of microbial study, Dr. Nash designed all-natural cattle feed additives to inhibit a dangerous E. coli 1057:H7 strain and improve feed efficiency with "impressive results." Dr. Nash holds three patents as a result of his work and has many international patents pending.

Announcing the appointment, Monte Tobin, CEO, said, "Peter brings with him a combination of both research and scientific applications experience in antibody production for animal use which will help commercially expand our unique product set for distribution into our targeted animal markets."

On his new appointment, Dr. Nash said, "This is an exciting opportunity for me to join one of the most creative organizations in this field. The company's recent work and stated direction into this highly profitable, yet underserved market, will allow me to continue my research and development of new and efficient ways to use antibodies to strengthen the health of all animals intended for human consumption."

About Mach One Corporation

Through its wholly-owned subsidiary VDx, Inc. ( www.vdxinc.com ), the company currently manufactures and sells Immunogam (TM) , a colostrums replacement, supplement and prophylactic, in sterile powder form, which can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market that includes an added ingredient for elimination of mastitis and Johnnes disease.

Safe Harbor Statement

This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.

SOURCE Mach One Corporation

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.